FDA approves NASH liver disease drug from Madrigal Pharmaceuticals

[Pelican Press 0]

FDA approves NASH liver ******** ***** from Madrigal Pharmaceuticals

In this photo illustration, the Madrigal Pharmaceuticals logo is displayed on a smartphone screen. 

Rafael Henrique | SOPA Images | Lightrocket | Getty Images

The Food and ***** Administration on Thursday

This is the hidden content, please

• Sign In
• or
• Sign Up

the first-ever treatment for a common and potentially deadly

This is the hidden content, please

• Sign In
• or
• Sign Up

that affects millions worldwide.

The FDA’s decision means Madrigal Pharmaceuticals has succeeded in a ******** area that several larger companies have ******* — or are still trying to break into. Shares of the Madrigal jumped more than 20% in extended trading Thursday following the approval.

Novo Nordisk and Eli Lilly are testing their respective blockbuster weight loss injections as treatments for the same kind of liver ********, called non-alcoholic steatohepatitis, or NASH.

Madrigal’s *****, which will be marketed as Rezdiffra, is specifically approved to treat patients with NASH who also have moderate-to-advanced liver scarring. The treatment must be used with diet and exercise, according to the FDA.

NASH is a serious form of liver ******** characterized by excess **** buildup and inflammation in the liver and can lead to liver scarring, also known as fibrosis, along with liver ******** and liver *******. The condition is often associated with other health problems, such as high blood pressure, Type 2 diabetes and obesity.

Roughly 6 to 8 million people in the U.S. have NASH with moderate to advanced liver scarring, according to an

This is the hidden content, please

• Sign In
• or
• Sign Up

cited by the FDA.

Madrigal said in a statement that the ***** will be available in April. The company also said it has set up an assistance program to help people who don’t have insurance access Rezdiffra. Madrigal has not disclosed how much the treatment will be.

“Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage,” said Dr. Nikolay Nikolov, acting director of the FDA’s Office of Immunology and Inflammation.

Madrigal’s ***** specifically received an “accelerated approval “from the FDA. That designation clears drugs faster if they fill an unmet medical need for serious conditions, and requires Madrigal to further study the treatment and verify its clinical benefits.

MadrigaL’s medication works by activating a thyroid hormone receptor in the liver to help reduce **** accumulation. Patients take it by mouth each day.

In a late-stage

This is the hidden content, please

• Sign In
• or
• Sign Up

published last month, Rezdiffra helped resolve symptoms of NASH and improve liver scarring without making the condition worse. Notably, the rate of serious adverse events was comparable between the patient group that took the ***** and another group that received a placebo.

The most common side effects related to treatment were diarrhea, nausea and vomiting. 

Some specialists have started calling NASH

This is the hidden content, please

• Sign In
• or
• Sign Up

 to avoid potentially stigmatizing language.

This is the hidden content, please

• Sign In
• or
• Sign Up

Breaking News: Business,Business,Biotechnology,Biotech and Pharmaceuticals,Pharmaceuticals,Health care industry,Madrigal Pharmaceuticals Inc,Novo Nordisk A/S,Eli Lilly and Co,Novo Nordisk A/S,business news
#FDA #approves #NASH #liver #******** #***** #Madrigal #Pharmaceuticals

This is the hidden content, please

• Sign In
• or
• Sign Up